Syneos Health (SYNH) Stock Price
Syneos Health Price
Over the last 11 years Syneos Health grew revenue by 21.1% annually, reaching 5.39 B USD. Earnings per share have grown at 3.6% per year over the last 7 years. For Syneos Health, the net margin of 4.9% is up versus 0.6% a few years ago.
Syneos Health stock price
Syneos Health business model & stock analysis
Frequently asked questions about Syneos Health
Syneos Health Inc operates as a leading global contract research organization (CRO) that provides integrated solutions to the pharmaceutical and biotechnology industries. The company offers a comprehensive range of services, including clinical development, commercialization, and consulting, aimed at accelerating the delivery of innovative therapies to patients. Syneos Health's business model focuses on leveraging its expertise, technology, and extensive network of resources to support clients in bringing new drugs and treatments to market efficiently. By combining clinical and commercial insights, the company aims to streamline the drug development process and improve the overall success rate for its clients. Syneos Health Inc is committed to revolutionizing the clinical research industry and advancing healthcare outcomes globally.
Syneos Health Inc is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Syneos Health Inc in the market include IQVIA Holdings Inc, PRA Health Sciences, Inc, and Icon Plc.
Syneos Health Inc is a leading global contract research organization (CRO) that provides integrated clinical and commercial solutions to the biopharmaceutical industry. The company was formed in 2017 through the merger of inVentiv Health and INC Research, both renowned industry players. Syneos Health has a rich history of excellence and innovation in delivering end-to-end services and expertise across the drug development and commercialization continuum. With a team of over 25,000 professionals worldwide, Syneos Health is dedicated to improving healthcare by helping customers accelerate the development and delivery of therapies and treatments.
Syneos Health Inc has achieved several significant milestones in its journey. One remarkable milestone was the merger of INC Research and inVentiv Health in 2017, creating Syneos Health Inc. This strategic combination allowed the company to offer end-to-end solutions to clients in the biopharmaceutical industry. Additionally, Syneos Health Inc became the first fully-integrated biopharmaceutical solutions organization, delivering innovative and efficient strategies for clinical development and commercialization. Furthermore, the company has expanded its global footprint by establishing a strong presence in over 40 countries worldwide. These achievements demonstrate Syneos Health Inc's commitment to providing comprehensive services and driving growth and success in the biopharmaceutical sector.
Syneos Health Inc primarily operates in numerous countries and regions around the world. With a global presence, the company offers its services in North America, Europe, Asia-Pacific, and other key markets. Syneos Health Inc has established a strong foothold in the United States, where it is headquartered, and has expanded its reach across various European countries such as the United Kingdom, Germany, France, and Switzerland. Additionally, the company has a significant presence in Asia-Pacific countries like Japan, China, India, and Australia. Through its extensive geographical coverage, Syneos Health Inc demonstrates its commitment to serving clients and conducting clinical trials on a global scale.
Syneos Health Inc. represents a commitment to healthcare innovation and collaboration. As a top global biopharmaceutical solutions organization, the company prioritizes the values of integrity, accountability, and agility. With a focus on delivering end-to-end solutions to clients, Syneos Health strives to accelerate the development of breakthrough therapies. The corporate philosophy revolves around empowering its customers with the expertise, technology, and insights required for successful drug development and commercialization. Through its comprehensive range of services, Syneos Health is dedicated to driving clinical innovation, increasing efficiency, and ultimately improving patient lives.
16 analysts currently rate the Syneos Health stock: 0 recommend buying, 13 holding and 3 selling.
Converted at the current exchange rate, the Syneos Health share trades at 38.35 EUR (42.98 USD).
The Syneos Health share (SYNH) is listed on 4 stock exchanges, including: NASDAQ (SYNH), Frankfurt (8IN.F), München (8IN.MU), Düsseldorf (8IN.DU).
Syneos Health Inc is a company that specializes in supporting biotechnology and pharmaceutical companies in the development and marketing of products. The company's business model is based on four main areas: Clinical Solutions, Commercial Solutions, Consulting and Insights, and Medical Communications.
The revenue cannot currently be calculated for Syneos Health.
The profit cannot currently be calculated for Syneos Health.
The P/E ratio cannot be calculated for Syneos Health at the moment.
The P/S cannot be calculated for Syneos Health currently.
The Eulerpool Quality Score for Syneos Health is 3/10.
The ISIN of Syneos Health is US87166B1026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Syneos Health is A2JBKW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Syneos Health is SYNH. The ticker symbol is used to trade Syneos Health shares on the stock exchange.
Syneos Health stock
Syneos Health Peer Group
Syneos Health Ticker
Syneos Health FIGI
All fundamentals and in-depth analysis of Syneos Health
Our stock analysis for Syneos Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syneos Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.